Search Results - "Pishvaian, M.J"

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC) by Pishvaian, M.J., Lee, M.S., Ryoo, B.-Y., Stein, S., Lee, K.-H., Verret, W., Spahn, J., Shao, H., Liu, B., Iizuka, K., Hsu, C.-H.

Get full text

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 by Ott, P.A, Piha-Paul, S.A, Munster, P, Pishvaian, M.J, Van Brummelen, E, Cohen, R, Gomez-Roca, C, Ejadi, S, Stein, M, Chan, E, Simonelli, M, Morosky, A, Yuan, S.S, Koshiji, M, Bennouna, J

Get full text

Stereotactic Body Radiation Therapy (SBRT) with Concurrent Full-Dose Gemcitabine for Locally Advanced Pancreatic Cancer: A Pilot Trial Demonstrating Safety by Pishvaian, M.J, Slack, R, Charabaty, A, Ley, L, Berzcel, L, Nakles, R, Jha, R, Jackson, P, Haddad, N, Collins, S.P

Get full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal by Ott, P.A., Piha-Paul, S.A., Munster, P., Pishvaian, M.J., van Brummelen, E.M.J., Cohen, R.B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.

“…Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for…”
Get full text

418 POSTER A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT) by Pishvaian, M.J, Hwang, J.H, Malik, S, He, A.R, Deeken, J.F, Kelso, C.B, Dorsch-Vogel, K, Berger, M.S, Marshall, J.L

Get full text

409 POSTER A Phase I clinical trial of the oral PPAR gamma agonist, CS-7017 in patients with advanced malignancies by Pishvaian, M.J, Wagner, A, Deeken, J, He, A.R, Hwang, J, Malik, S, Cotarla, I, Demetri, G, Marshall, J.L, Wojtowicz-Praga, S

Get full text

Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients by Carrier, E., Picozzi, V., Pishvaian, M.J., Mody, K., Winter, J., Glaspy, J., Larson, T., Conway, W.C., Lipson, K., Porter, S., Kouchakji, E.

Get full text

A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL by Naing, A., Leong, S., Pishvaian, M.J., Razak, A.R.A., Mahipal, A., Berlin, J., Cho, D., Senapedis, W., Shacham, S., Kauffman, M., Ellis, J., Meade, J., Baloglu, E.

Get full text

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study by He, A.R., Weiss, G.J., Falchook, G., Yee, N.S., Gil-Martin, M., Shahda, S., Moreno, V., Brana, I., Crittenden, M., Formenti, S., Al-Rajabi, R., Papadopoulos, K.P., Pishvaian, M.J., Stankevich, E., Feng, M., Li, J., Mathias, M., Kroog, G., Lowy, I., Fury, M.G.

Get full text

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS by Lieu, C., Bendell, J., Powderly, J.D., Pishvaian, M.J., Hochster, H., Eckhardt, S.G., Funke, R., Rossi, C., Waterkamp, D., Hurwitz, H.

“…Abstract Aim: PD-L1 mediates cancer immune evasion, and blocking PD-L1 represents a cancer immunotherapy strategy that can restore tumor-specific T-cell…”
Get full text

Safety and Efficacy of Mpdl3280A (Anti-Pdl1) in Combination with Bevacizumab (Bev) and/or Chemotherapy (Chemo) in Patients (Pts) with Locally Advanced or Metastatic Solid Tumors by Lieu, C., Bendell, J., Powderly, J.D., Pishvaian, M.J., Hochster, H., Eckhardt, S.G., Funke, R., Rossi, C., Waterkamp, D., Hurwitz, H.

Get full text

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study by Pishvaian, M.J., Weiss, G.J., Falchook, G.S., Yee, N., Gil-Martin, M., Shahda, S., Moreno, V., Brana, I., Crittenden, M., Formenti, S., Al-Rajabi, R., Papadopoulos, K.P., Stankevich, E., Feng, M., Li, J., Mathias, M., Kroog, G., Lowy, I., Fury, M.G.

Get full text

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study by Mehnert, J.M., Rugo, H.S., O'Neil, B.H., Santoro, A., Schellens, J.H.M., Cohen, R.B., Doi, T., Ott, P.A., Pishvaian, M.J., Puzanov, I., Aung, K.L., Hsu, C., Le Tourneau, C., Soria, J-C., Elez, E., Tamura, K., Gould, M., Zhao, G., Stein, K., Piha-Paul, S.A.

Get full text